Delve Bio
Delve Bio is on a mission to revolutionize infectious disease testing by bringing metagenomic (mNGS) testing into clinical practice. They develop and provide advanced metagenomic sequencing solutions, including Delve Detect, to enable rapid, comprehensive pathogen detection from a single sample. Their technology aims to improve diagnostic accuracy, reduce turnaround times, and support clinicians in making informed treatment decisions, especially for neurological infections. Backed by extensive clinical data and research collaborations, Delve Bio strives to make mNGS a standard of care in infectious disease diagnostics.
Industries
Nr. of Employees
small (1-50)
Delve Bio
Delve Bio, 1234 Innovation Drive, San Francisco, CA 94158
Products
Clinical metagenomic sequencing test for cerebrospinal fluid (CSF)
A clinical diagnostic test that sequences and analyzes nucleic acids in CSF to identify infectious agents across bacteria, viruses, fungi, and parasites and provides interpreted reports to guide clinical care.
Clinical metagenomic sequencing test for cerebrospinal fluid (CSF)
A clinical diagnostic test that sequences and analyzes nucleic acids in CSF to identify infectious agents across bacteria, viruses, fungi, and parasites and provides interpreted reports to guide clinical care.
Services
Laboratory service that accepts CSF samples and returns comprehensive metagenomic sequencing results for pathogen identification (DNA and RNA) with clinical interpretation.
Expert medical review and consult services to assist with patient identification, result interpretation, and clinical next steps following testing.
Provision of sample transfer kits suitable for room-temperature storage and prepaid shipping materials to support rapid overnight return of CSF specimens to the processing laboratory.
Operational partnership with CLIA-licensed and CAP-accredited sequencing operations to scale clinical sample processing and sequencing.
Laboratory service that accepts CSF samples and returns comprehensive metagenomic sequencing results for pathogen identification (DNA and RNA) with clinical interpretation.
Expert medical review and consult services to assist with patient identification, result interpretation, and clinical next steps following testing.
Provision of sample transfer kits suitable for room-temperature storage and prepaid shipping materials to support rapid overnight return of CSF specimens to the processing laboratory.
Operational partnership with CLIA-licensed and CAP-accredited sequencing operations to scale clinical sample processing and sequencing.
Expertise Areas
- Clinical metagenomic diagnostics
- Infectious disease diagnostics
- Clinical bioinformatics and pathogen detection
- Pathogen genomics and viral subtyping
Key Technologies
- Next-generation sequencing (NGS)
- Metagenomic sequencing (mNGS)
- RNA and DNA sequencing
- Nucleic acid enrichment for pathogens
News & Updates
Delve’s co-founder, Dr. Charles Chiu, discusses performance and stewardship of clinical metagenomics for CNS infections.
Partnership to rapidly scale up access to metagenomic testing for neurological infections.
Reduced turnaround time to a little over 48 hours for CNS infections, increasing enthusiasm and uptake.
Early viral subtyping can help manage patients with serious CNS infections.
A study demonstrating the long-term effectiveness of mNGS in diagnosing CNS infections.
Research published in NEJM validating the clinical utility of mNGS for neurological infections.
Delve’s co-founder, Dr. Charles Chiu, discusses performance and stewardship of clinical metagenomics for CNS infections.
Partnership to rapidly scale up access to metagenomic testing for neurological infections.
Reduced turnaround time to a little over 48 hours for CNS infections, increasing enthusiasm and uptake.
Early viral subtyping can help manage patients with serious CNS infections.
A study demonstrating the long-term effectiveness of mNGS in diagnosing CNS infections.
Research published in NEJM validating the clinical utility of mNGS for neurological infections.